Recent News

• DOR/ISL 100 mg/0.25 mg QD in HIV-1 antiretroviral treatment naive
• Follow-up of Participants Who Received DOR/ISL (100 mg/0.75 mg)
• Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen
• A Phase 3 trial to assess efficacy and safety of M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered to adolescents and adults
• This is an interventional, randomised, double-blind, placebo-controlled, two-armed, parallel-group, multicentre, multinational clinical study